1. Home
  2. VGZ vs PROK Comparison

VGZ vs PROK Comparison

Compare VGZ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$2.03

Market Cap

295.7M

Sector

N/A

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$1.82

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
PROK
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.7M
296.8M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VGZ
PROK
Price
$2.03
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$3.75
$7.40
AVG Volume (30 Days)
1.2M
973.1K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1075.00
52 Week Low
$0.88
$0.54
52 Week High
$3.13
$7.13

Technical Indicators

Market Signals
Indicator
VGZ
PROK
Relative Strength Index (RSI) 44.63 41.55
Support Level $1.75 $1.71
Resistance Level $2.46 $2.58
Average True Range (ATR) 0.10 0.12
MACD 0.01 -0.01
Stochastic Oscillator 19.44 15.91

Price Performance

Historical Comparison
VGZ
PROK

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: